Norges Bank Takes $24.03 Million Position in Repligen Co. (NASDAQ:RGEN)

Norges Bank acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 166,975 shares of the biotechnology company's stock, valued at approximately $24,034,000. Norges Bank owned about 0.30% of Repligen at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Signaturefd LLC lifted its holdings in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after buying an additional 124 shares during the last quarter. Sava Infond d.o.o. bought a new position in Repligen during the fourth quarter valued at approximately $29,000. Resources Management Corp CT ADV acquired a new stake in Repligen in the third quarter valued at approximately $37,000. Quarry LP grew its position in Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 239 shares in the last quarter. Finally, UMB Bank n.a. increased its stake in shares of Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 110 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Stock Performance

RGEN stock traded up $7.67 on Friday, reaching $122.86. 978,190 shares of the company were exchanged, compared to its average volume of 702,020. The firm has a market capitalization of $6.90 billion, a PE ratio of -240.90, a PEG ratio of 4.54 and a beta of 1.27. Repligen Co. has a 12 month low of $102.97 and a 12 month high of $182.52. The stock's fifty day moving average price is $143.12 and its 200 day moving average price is $146.32. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Remove Ads

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, research analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of the firm's stock in a transaction on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on RGEN. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research note on Friday, April 4th. JPMorgan Chase & Co. upped their price target on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective on the stock. Evercore ISI initiated coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 target price for the company. Finally, Canaccord Genuity Group increased their price target on Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a report on Friday, February 21st. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and an average price target of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.